__NUXT_JSONP__("/drugs/Ruxolitinib_Phosphate", (function(a,b,c){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[{brand:"OPZELURA",indication:"1 INDICATIONS AND USAGE OPZELURA is indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Limitation of Use: Use of OPZELURA in combination with therapeutic biologics, other JAK inhibitors or potent immunosuppressants such as azathioprine or cyclosporine is not recommended. OPZELURA is a Janus kinase (JAK) inhibitor indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. ( 1 ) Limitation of Use Use of OPZELURA in combination with therapeutic biologics, other JAK inhibitors or potent immunosuppressants such as azathioprine or cyclosporine is not recommended. ( 1 )",manufacturer:"Incyte Corporation",splSetId:"24da5509-6631-4795-9d42-273faecd08e7"}],id:a,nciThesaurus:{casRegistry:"1092939-17-7",chebiId:"",chemicalFormula:"C17H18N6H3O4P",definition:"The phosphate salt form of ruxolitinib, an orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.",fdaUniiCode:"436LRU32H5",identifier:"C97937",preferredName:b,semanticType:"Organic Chemical",subclassOf:["C125450","C129650"],synonyms:["(3R)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)propanenitrile Phosphate (1:1)","1H-Pyrazole-1-propanenitrile, beta-cyclopentyl-4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-,(betaR)-, phosphate (1:1)","INCB-18424 Phosphate","Jakafi","RUXOLITINIB PHOSPHATE",b]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FRuxolitinib_Phosphate",extension:".json",createdAt:c,updatedAt:c}}],fetch:{},mutations:void 0}}("Ruxolitinib_Phosphate","Ruxolitinib Phosphate","2021-10-30T13:48:39.513Z")));